{"id":"W4404455235","doi":"10.25251/skin.8.supp.473","title":"Bimekizumab Efficacy and Safety Through 2 years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II trials and Open-Label Extension BE HEARD EXT","year":2024,"lang":"en","type":"article","venue":"SKIN The Journal of Cutaneous Medicine","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Geotab (Canada)","funders":"LEO Pharma; InflaRx; Idorsia Pharmaceuticals; European Academy of Dermatology and Venereology; Eisai; Bundesministerium für Bildung und Forschung; Insmed; Incyte; Celgene; Biogen; L'Oreal USA; European Commission; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hidradenitis suppurativa; Open label; Extension (predicate logic); Phase (matter); Medicine; Dermatology; Internal medicine; Clinical trial; Computer science; Chemistry; Programming language","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005473221,0.000936224,0.002282431,0.0003952536,0.0005527225,0.001289682,0.0006972818,0.00147052,0.004624122],"category_scores_gemma":[0.003708798,0.0005115418,0.002923984,0.0005958678,0.0005576512,0.001729009,0.0006826154,0.002749545,0.0007426367],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007399617,"about_ca_system_score_gemma":0.001092431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009891113,"about_ca_topic_score_gemma":0.002448736,"domain_scores_codex":[0.9980692,0.001047934,0.0001580237,0.0002487825,0.0002420701,0.0002339057],"domain_scores_gemma":[0.996821,0.0007329338,0.001149352,0.0002396011,0.0002560508,0.0008010151],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8496249,0.01398979,0.01589788,0.002704259,0.005271784,0.0001626688,0.0002929097,0.0008596558,0.005035296,0.0001974416,0.005951341,0.100012],"study_design_scores_gemma":[0.6300596,0.2775742,0.07711872,0.0003953902,0.004758259,0.0003952704,0.0001724072,0.0007229878,0.001606338,0.000334119,0.006774579,0.00008814402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9467441,0.03793798,0.0006400607,0.001316675,0.0003221298,0.002703722,0.00548594,0.00009108307,0.00475848],"genre_scores_gemma":[0.9766774,0.008728726,0.001212076,0.001860459,0.0008114947,0.002450984,0.005870137,0.0000292708,0.00235938],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005473221,"threshold_uncertainty_score":0.02894551,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07663420508063443,"score_gpt":0.3691144696220155,"score_spread":0.2924802645413811,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}